
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Overactive Bladder from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/overactive-bladder/topic/15927/</link>
        <description>Articles tagged with Overactive Bladder from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>OAB drugs draw flak for allegedly weak efficacy</title>
          <description>An FDA advisory panel endorsed Astellas&apos; overactive bladder medication mirabegron April 6, but not everyone is on board.</description>
          <link>http://www.mmm-online.com/oab-drugs-draw-flak-for-allegedly-weak-efficacy/article/236108/</link>
          <pubDate>Wed, 11 Apr 2012 19:15:53 GMT</pubDate>
          <itunes:summary>An FDA advisory panel endorsed Astellas&apos; overactive bladder medication mirabegron April 6, but not everyone is on board.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>DDR on DTC: Toviaz vs. Vesicare</title>
          <description>Two brands are fighting for attention from OAB sufferers: GSK-Astellas&apos;s Vesicare and Pfizer&apos;s Toviaz. Their DTC approaches couldn&apos;t be more different.</description>
          <link>http://www.mmm-online.com/ddr-on-dtc-toviaz-vs-vesicare/article/228908/</link>
          <pubDate>Thu, 01 Mar 2012 05:00:00 GMT</pubDate>
          <itunes:summary>Two brands are fighting for attention from OAB sufferers: GSK-Astellas&apos;s Vesicare and Pfizer&apos;s Toviaz. Their DTC approaches couldn&apos;t be more different.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  